German Digital Care Act: Industry Experts Examine The New Law’s Impact In 13th MedTech Radar

With the new Digital Care Act (“Digitale-Versorgung-Gesetz”, DVG), the German digital health scene is gaining momentum. However, what potential does it offer for healthcare in Germany, and where do companies still see a need for improvement? These topics will be covered in the joint publication “MedTech Radar” of the German Medical Technology Association (BVMed), Earlybird Venture Capital, the High-Tech Gründerfonds (HTGF) and the magazine medtech zwo. The13th MedTech Radar edition is available for download in German and English:

The DVG brings great hope of speeding up adoption of digital health tools in Germany. For the first time, public health insurance funds will now be able to reimburse digital health tools such as digital therapeutics and telehealth video consultation hours. Most of the medtech industry representatives welcome the law but believe that there is room for improvement in terms of the details and its implementation. The current issue of MedTech Radar covers the perspective of the medtech industry and start-ups in this space. Gottfried Ludewig, Head of Digitalization at the German Federal Ministry of Health, provides insights on the main motivation behind the new law.

“The lower barrier to entry and the patient-friendly approach make it possible for novel solutions to actually find their way into healthcare,”

says BVMed Managing Director Dr. Marc-Pierre Möll. However, the Medtech Association criticizes the fact that the new regulations initially only apply to medical product classes I and IIa.

“From BVMed’s point of view, it is necessary to broaden the scope of application to medical products in classes IIb and III. If this does not happen, the possibilities offered by digital health applications for the improvement of care will be very limited,”

says Natalie Gladkov, BVMed’s expert for digital medical devices.

For Anke Caßing, investment manager at High-Tech Gründerfonds, the DVG is an innovation driver with high potential:

“The law may not yet regulate everything perfectly, but it offers a unique opportunity for start-ups to obtain access to digital solutions and to broadly improve patient care. I am sure that founders, investors and other players will seize this opportunity, exchange experiences and make constructive suggestions for improvement.”

Thom Rasche, partner at Earlybird, also emphasizes the positive impact of the new law:

“The law will pave the way for transferring digital care to standard clinical practice. It will encourage the health insurers to try out innovations, and also increase their engagement through investments into venture capital funds. The decisive success factor of the law, however, will be its interpretation and the implementation of the text in practice. All parties involved in the healthcare system, including the regulators, should see it as an opportunity.”

Sandra Wirsching, Editor-in-chief of the medtech zwo magazine, comments:

“With the DVG, Germany will finally gain access to a growing global market. For too long, digital health start-ups in Germany struggled with market entry barriers. This should now change, providing a strong innovation boost in the long-term.”

About the publishers

Earlybird is a venture capital investor focused on technology companies in Europe. Founded in 1997, Earlybird focuses on investments in various growth phases of the company’s development. Earlybird is one of Europe’s most experienced venture capitalists, managing digital technology funds in Eastern and Western Europe and health care funds.

Earlybird Venture Capital
Münzstr. 21
10178 Berlin
Catrin Schmidt
T.: +49 – 30 46724700

The German Medical Technology Association (BVMed) is a trade association representing over 230 industrial and commercial companies in the medical technology sector.

BVMed – German Medical Technology Association
Reinhardtstrasse 29 b
10117 Berlin
Manfred Beeres, Head of Communication/Press
T.: +49 – 30 246 255-20

The magazine medtech zwo is published by BIOCOM AG. It reports on current developments in the fields of financing, technology, production and regulation of the medical technology industry in Germany, Austria and Switzerland.

BIOCOM AG & medtech zwo
Lützowstr. 33-36
10785 Berlin
Sandra Wirsching, Director of Business Development & Chief Editor medtech zwo
T.: +49 (0)30-264 921-63

High-Tech Gründerfonds invests venture capital in young, promising technology companies that implement promising research results in an entrepreneurial manner. The third fund was launched in 2018. Its investors include the German Federal Ministry of Economics and Energy, KfW Capital and 33 companies including Bayer, B.Braun, Boehringer Ingelheim and Dräger.

High-Tech Gründerfonds Management GmbH
Schlegelstrasse 2
53113 Bonn, Germany
Cornelia Mann, Marketing & Communications
T.: +49 – 228 82300121

More posts

23. May 2023

smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

Munich, Germany, May 23, 2023 – smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million. The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific tea
15. May 2023

Using an app to combat skin conditions: Nia Health receives millions in funding

The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round. The company originates from the Charité Universitätsmedizin Berlin and operates leading dermatology apps, including "Nia," the most widely downloaded app for people with atopic dermatitis. The company has a network of renowned cooperation partners consisting of pharmaceutical companies, health insurance companies and clinics. The great potential lies above all in Nia Health's ex
Dualyx Logo
15. May 2023

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates Financing co-led by Fountain Healthcare Partners, Forbion and Andera Partners with support from existing investors Bernard Coulie appointed as Independent Chairman with immediate effect May 15, 2023, Ghent, Belgium – Dualyx NV, a Ghent based biotech developing next generation immune modulators, today announces that it has